In the phase III FLAURA study, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free survival (PFS) versus standard-of-care (SoC) EGFR-TKI (gefitinib or erlotinib), in patients with previously untreated EGFR (exon 19 deletion or L858R) mutation-positive advanced NSCLC. Interim overall survival data were encouraging but not formally statistically significant at current maturity (25%). Here we report exploratory post-progression outcomes.
All post-progression endpoints showed consistent improvement with osimertinib versus SoC EGFR-TKI, providing further confidence in the interim overall survival data.
http://clincancerres.aacrjournals.org/content/early/2019/01/18/1078-0432.CCR-18-3325
